| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3295447 | Gastroenterology | 2012 | 13 Pages |
Abstract
Approximately 50% of patients with Crohn's disease who were treated for at least 1 year with infliximab and an antimetabolite agent experienced a relapse within 1 year after discontinuation of infliximab. However, patients with a low risk of relapse can be identified using a combination of clinical and biologic markers.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Edouard Louis, Jean-Yves Mary, Gwenola Vernier-Massouille, Jean-Charles Grimaud, Yoram Bouhnik, David Laharie, Jean-Louis Dupas, Hélène Pillant, Laurence Picon, Michel Veyrac, Mathurin Flamant, Guillaume Savoye, Raymond Jian, Martine DeVos,